Tuberculosis is a major infectious disease that seriously endangers the health of the people of our country. my country still ranks third in the world with an incidence rate of 68/100,000. Carrying out research on new tuberculosis vaccines, diagnostics and drugs is still an extremely important part of our country's tuberculosis control strategy. In the treatment of tuberculosis, irregular treatment, withdrawal or even treatment failure caused by low weight, excessive drugs taken by the patient every day, and excessive hepatotoxicity have seriously affected the survival and quality of life of the patient, and it also leads to drug-resistant tuberculosis. The root cause of the occurrence.
In the clinical treatment of tuberculosis, whether it is for initial treatment (2HREZ/4HR) or retreatment (2HREZS/6HRE), rifampicin is the core drug in short-course standard chemotherapy. In response to the above problems, Shenyang Hongqi Pharmaceutical Co., Ltd., with a sense of mission and responsibility, conducted a multi-center clinical evaluation of Rifampicin Capsule II independently developed and produced, aiming to use a smaller dose, lower liver toxicity, and greater compliance. Good Rifampicin Capsule II provides clinicians with better treatment options and brings greater benefits to patients.
The full name of the project is "Multi-center clinical evaluation of anti-tuberculosis drug Rifampicin Capsule (II) for the treatment of tuberculosis". It is a special clinical evaluation project initiated by Shenyang Hongqi Pharmaceutical Co., Ltd., responsible for the China National Tuberculosis Association, and participating in eight tuberculosis hospitals across the country. This project was officially launched in Xuzhou on February 24, 2017. It was chaired by Researcher Zhao Yanlin, Deputy Director of the Tuberculosis Prevention and Control Center of China Center for Disease Control and Prevention. Professor Cheng Shiming, Secretary-General of China National Tuberculosis Association, made unified deployment and training for the entire project. Director Zhou Lin of the Patient Care Department of CDC Control Center, Mr. Yang Bo, general manager of Shenyang Hongqi, as well as leaders of related departments and project leaders of various hospitals attended the meeting as nonvoting delegates.
This is a landmark clinical evaluation project. It is the first large-scale multi-center clinical study of the anti-tuberculosis drug rifampicin. The China National Tuberculosis Association is the national authority for tuberculosis prevention and treatment. Project plan and case analysis table , Informed Consent and other relevant materials are fully carried out in accordance with standard clinical evaluation standards.
Shenyang Hongqi Pharmaceutical Co., Ltd. provides all evaluation drugs for free, and has invested a lot of manpower, material and financial resources to support the smooth development of this project. As of the date of publication, within 2 months, the China National Tuberculosis Association, 8 centers and Shenyang Together with Hongqi, they have completed the signing of agreements, allocation of funds, distribution of materials, availability of medicines, and skills training, and have begun to enroll cases. As of the date of publication, a total of 38 patients have been enrolled, and the progress is very smooth. !
The project is proceeding quickly and orderly in accordance with the established plan. The China National Tuberculosis Association and Shenyang Hongqi will continue to follow up the progress of the project in a rigorous and responsible professional spirit, solve problems in time, and ensure that the project is completed on schedule.